A double-blind, randomised, placebo-controlled, first-in-human (FIH) Phase I/IIa, multi-centre trial to assess safety, tolerability, and immune response of single and multiple ascending doses of TOL2 (Immune Tolerising Agent) in patients with generalised myasthenia gravis
Not yet recruitingCTIS2024-515627-10-00
Toleranzia ABgeneralised myasthenia gravis
Target: 42Updated: 2025-02-12